Biotech Frontiers

Life-science and biotech investing is our focus in Biotech Frontiers… Some startups follow a clear, smooth path to success. Others skyrocket, then quickly fall back to Earth. But, generally speaking, as a sector, biotech stocks perform differently than tech stocks, “forever stocks,” and certainly the blue chips… Biotech veteran Erez Kalir heads up this advisory that publishes on the first Thursday of each month, with regular unscheduled updates as they are needed.

Issues & Updates


  • The Next MicroStrategy
    For those who have successfully ridden the MicroStrategy train – seeing huge gains on investments into Bitcoin – congratulations. For those who have not ridden that train, this issue of Biotech Frontiers will offer you a similar opportunity: a recommendation of a company that is now as little-known as MicroStrategy was back in 2020, with very real potential for similar upside.
    Read More
  • Spare Parts For Humans
    A leader in the field of regenerative medicine, this company has developed treatment for injured civilians and soldiers in Ukraine, and for vascular victims of automobile accidents, shootings, and industrial mishaps. Its off-the-shelf solution is putting it way ahead of its competition… with a potential for huge future returns.
    Read More
  • Sell Alert: Sell Shares of uniQure (QURE)
    This morning, uniQure (Nasdaq: QURE) – which we originally recommended as part of our basket of 10 negative-EV stocks in January with an entry price of $6.62, and recommended again as a standalone pick in October with an entry price of $4.54 – issued a press release announcing that the company has reached an agreement
    Read More
  • Trump’s Inflation Triggers
    In this issue, analyst Erez Kalir focuses on a Big Picture inflection point that he says is crucially important for biotech holdings as well as every other investment in an investor’s portfolio.
    Read More
See All Issues & Updates

Special Reports

America’s Last Election

See All Special Reports